The management of recurrent and drug-resistant gestational trophoblastic neoplasia (GTN) (Q35582586)

9 August 2017

1 reference

title

The management of recurrent and drug-resistant gestational trophoblastic neoplasia (GTN) (English)

1 reference

https://api.crossref.org/works/10.1016/S1521-6934(03)00092-0

1 April 2024

E. S. Newlands

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14614889

1 April 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14614889

1 April 2024

publication date

1 December 2003

1 reference

full work available at URL

9 August 2017

https://api.elsevier.com/content/article/PII:S1521693403000920?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S1521-6934(03)00092-0

https://api.elsevier.com/content/article/PII:S1521693403000920?httpAccept=text/plain

1 April 2024

1 reference

https://api.crossref.org/works/10.1016/S1521-6934(03)00092-0

Best Practice & Research: Clinical Obstetrics & Gynaecology

1 April 2024

published in

1 reference

9 August 2017

1 reference

9 August 2017

1 reference

9 August 2017

page(s)

905-923

1 reference

FIGO staging for gestational trophoblastic neoplasia 2000. FIGO Oncology Committee

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900092-0

7 January 2021

Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900092-0

7 January 2021

EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900092-0

7 January 2021

Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastati

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900092-0

7 January 2021

Chemotherapy for gestational trophoblastic tumours hastens menopause by 3 years

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900092-0

7 January 2021

Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900092-0

7 January 2021

Influence of chemotherapy for gestational trophoblastic disease on subsequent pregnancy outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900092-0

7 January 2021

Remission of refractory gestational trophoblastic disease with high-dose paclitaxel.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900092-0

7 January 2021

Successful treatment of mother and baby with metastatic choriocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900092-0

7 January 2021

Phase II trial of gemcitabine in refractory germ cell tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900092-0

7 January 2021

Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900092-0

7 January 2021

High-Dose Chemotherapy with Autologous Bone Marrow Transplantation for Refractory Metastatic Gestational Trophoblastic Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900092-0

7 January 2021

Choriocarcinoma and epithelial trophoblastic tumor: successful treatment of relapse with hysterectomy and high-dose chemotherapy with peripheral stem cell support: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900092-0

7 January 2021

Expression of epidermal growth factor receptor-related family products in gestational trophoblastic diseases and normal placenta and its relationship with development of postmolar tumor

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900092-0

7 January 2021

Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900092-0

7 January 2021

Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900092-0

7 January 2021

Oxaliplatin and UFT combination chemotherapy in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900092-0

7 January 2021

Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900092-0

7 January 2021

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900092-0

7 January 2021

Pemetrexed disodium, a novel antifolate with multiple targets

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900092-0

7 January 2021

Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900092-0

7 January 2021

Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900092-0

7 January 2021

Management of brain metastases in patients with high-risk gestational trophoblastic tumors

1 reference

https://api.crossref.org/works/10.1016/S1521-6934(03)00092-0

Capecitabine in the management of colorectal cancer

1 April 2024

1 reference

https://api.crossref.org/works/10.1016/S1521-6934(03)00092-0

Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model

1 April 2024

1 reference

https://api.crossref.org/works/10.1016/S1521-6934(03)00092-0

1 April 2024

Identifiers

1 reference

9 August 2017

1 reference